Transduction vector based on modified HIV-2
OwnerJames Gilbert, Frank Parkinventors
Life of this patent
Estimating the term…
Abstract
A lentiviral vector system for gene transfer and gene therapy is disclosed. The system is based on human immunodeficiency virus type 2 (HIV-2), and uses a split-genome approach. The vector system can integrate into a host genome regardless of cell division. It may be used in terminally-differentiated cells. It has a high cloning capacity, between 8-11 kb. Minimal viral sequence is integrated into the host genome, reducing the likelihood that replication-competent viral particles will form following integration. HIV-2 is less pathogenic than HIV-1. By using different envelope proteins in the vector, the tropism may be targeted to particular cell types.
Claims8
A construct for transducing both dividing and non-dividing mammalian cells;
- said construct comprising at least four different plasmids:
- a packaging plasmid, an envelope plasmid, a transfer plasmid, and a Rev-expressing plasmid;
- wherein:
- (a) said packaging plasmid comprises a DNA oligonucleotide encoding HIV-2 gag, operably linked to a promoter that is functional in mammalian cells;
- and said packaging plasmid comprises a DNA oligonucleotide encoding HIV-2 pol, operably linked to a promoter that is functional in mammalian cells;
- and said packaging plasmid does not comprise an HIV-2 ψ sequence;
- and said plasmid does not comprise a 3′ long terminal repeat;
- and said plasmid does not comprise a 5′ long terminal repeat;
- (b) said envelope plasmid comprises a DNA oligonucleotide encoding a viral envelope protein, operably linked to a promoter that is functional in mammalian cells;
- wherein said envelope plasmid does not include any oligonucleotide that encodes any non-envelope HIV-1 or HIV-2, operably linked to a promoter that is functional in mammalian cells;
- (c) said transfer plasmid comprises an HIV-2 5′ R element;
- and an HIV-2 5′ U5 long terminal repeat;
- and an HIV-2 3′ R element;
- and an HIV-2 ψ sequence;
- and either a DNA oligonucleotide sequence recognized by a restriction enzyme, adapted to accept a cloned transgene, or a transgene that encodes a protein whose expression is desired in mammalian cells that are transduced with said construct;
- (d) said Rev-expressing plasmid comprises a DNA oligonucleotide encoding HIV-2 rev protein, operably linked to a promoter that is functional in mammalian cells;
- and
- (e) said construct comprises oligonucleotides that encode zero elements or one element, but not more than one element, selected from the group of elements consisting of HIV-2 tat, HIV-2 vpr, HIV-2 vpx, HIV-2 vif, and HIV-2 net, operably linked to a promoter that is functional in mammalian cells.
Dependencies are inferred from the claim text.